Research suggests a SARS‐CoV‐2 and HBV coinfection may increase adverse events at the onset of the virus. Have you seen this in your practice? Tell us with this quick poll.
Research suggests a SARS‐CoV‐2 and HBV coinfection may increase adverse events at the onset of the virus. Have you seen this in your practice? Tell us with this quick poll.
In a recent review, the American Gastroenterological Association (AGA) recommended what aspirin dosage for chemoprevention of neoplasia among patients with an average risk of colorectal cancer (CRC)? Find out with this quick quiz!
In a recent review, the American Gastroenterological Association (AGA) recommended what aspirin dosage for chemoprevention of neoplasia among patients with an average risk of colorectal cancer (CRC)? Find out with this quick quiz!
A recent study revealed which patients to be at risk for greater toxicity when treated with certain types of chemotherapy for colon cancer? Take our quick quiz and find out!
A recent study revealed which patients to be at risk for greater toxicity when treated with certain types of chemotherapy for colon cancer? Take our quick quiz and find out!
What type of food elimination treatment has demonstrated effectiveness among pediatric patients with eosinophilic esophagitis? Take our quiz and find out!
What type of food elimination treatment has demonstrated effectiveness among pediatric patients with eosinophilic esophagitis? Take our quiz and find out!
Vonoprazan offers an effective alternative treatment to intravenous proton pump inhibitors for prevention of rebleeding among patients with high-risk peptic ulcers, researchers found.
Vonoprazan offers an effective alternative treatment to intravenous proton pump inhibitors for prevention of rebleeding among patients with high-risk peptic ulcers, researchers found.
Results showed that a lower fibrosis stage (F0–1) was associated with a significantly reduced risk of cirrhosis and liver-related outcomes compared to patients with advanced fibrosis (F4).
Results showed that a lower fibrosis stage (F0–1) was associated with a significantly reduced risk of cirrhosis and liver-related outcomes compared to patients with advanced fibrosis (F4).
The U.S. Food and Drug Administration (FDA) on October 4 approved the Cologuard Plus multitarget stool DNA test for adults ages 45 and older who are average risk for colorectal cancer.
The U.S. Food and Drug Administration (FDA) on October 4 approved the Cologuard Plus multitarget stool DNA test for adults ages 45 and older who are average risk for colorectal cancer.